AngioDynamics (NSDQ:ANGO) won a green light from the FDA for a clinical trial of its NanoKnife device for treating prostate cancer.
Under an investigation device exemption from the federal watchdog agency, NanoKnife will study the NanoKnife soft tissue ablation device for focal prostate cancer ablation, according to a press release.
Albany, N.Y.-based AngioDynamics said it plans to enroll the 1st patient in the trial during the 2nd quarter of 2014. A separate, 200-patient NanoKnife trial is already under way in Europe for low-intermediate localized prostate cancer.
“AngioDynamics has made a long-term investment in the opportunity the NanoKnife System offers to physicians and their patients,” CEO Joseph DeVivo said in prepared remarks. “The place for this therapy is opening up as we pursue high quality evidence, and we look forward to sharing further details during our fourth quarter fiscal year 2013 earnings report and conference call.”
The Albany, N.Y.-based recently let go of its U.S. sales manager and announced an employee training plan in conjunction with AdvaMed’s efforts to repeal the medical device tax.
